Avacta announces AVA6000 dose escalation results
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
Read More
Tag: AVA6000
Avacta announces clinical study of AVA6000
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
